Today's Date
ActoBio AG019 (L. lactis) and teplizumab
(
INTREXON
)
ITN Protocol #:
ITN829AI
Branded Name:
INTREXON
Treatment Protocol #:
Therapeutic Area:
Type 1 Diabetes
Current Status:
Complete
Summary:
A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in subjects with clinical recent-onset Type 1 Diabetes Mellitus (T1D).
Clinical Operations Associate Director & Manager
ITN Biologist
Study Personnel:
